Vir Biotechnology Inc
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN ® dual-masked T-cell engagers iii across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website. Footnotes: i Huo, Xingyue et al. "Predicting Survival in Metastatic Castration-Resistant Prostate Cancer Patients: Development of a Prognostic Nomogram." Studies in health technology and informatics vol. 323 (2025): 164-168. doi:10.3233/SHTI250070 ii 50% premium to the 30 day volume weighted average share price as of February 19, 2026 iii Vir Biotechnology retains exclusive rights to the PRO-XTEN ® masking platform for oncology and infectious disease. PRO-XTEN ® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.
Current Price
$8.79
-3.30%Vir Biotechnology Inc (VIR) Stock Chart
VIR Interactive Stock Chart
Interactive stock chart for Vir Biotechnology Inc (VIR) with candlestick and line chart views. Analyze price action across multiple timeframes: 5 days, 1 week, 1 month, 3 months, 6 months, 1 year, 5 years, and full history.
Current price: $8.79. 52-week high: $11.09. 52-week low: $4.28. 50-day moving average: $9.63. 200-day moving average: $6.97.
Technical analysis indicators include Volume, SMA 20, SMA 50, SMA 200, EMA 20, and RSI. Toggle between candlestick and line chart styles. Overlay multiple moving averages to identify support and resistance levels, trend direction, and momentum signals for VIR. Use the chart alongside GoodMoat's fundamental analysis tools for a complete picture of Vir Biotechnology Inc's investment potential.